Head-To-Head Survey: Prestige Consumer Healthcare (NYSE:PBH) & Unicycive Therapeutics (NASDAQ:UNCY)

Prestige Consumer Healthcare (NYSE:PBH) and Unicycive Therapeutics (NASDAQ:UNCY) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Earnings and Valuation

This table compares Prestige Consumer Healthcare and Unicycive Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09 billion	2.00	$190.30 million	$3.57	12.88
Unicycive Therapeutics	N/A	N/A	-$26.56 million	($1.75)	-2.76

Prestige Consumer Healthcare has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prestige Consumer Healthcare and Unicycive Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Volatility and Risk

Prestige Consumer Healthcare has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Prestige Consumer Healthcare and Unicycive Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1	3	2	0	2.17
Unicycive Therapeutics	1	1	5	0	2.57

Prestige Consumer Healthcare presently has a consensus target price of $70.75, indicating a potential upside of 53.90%. Unicycive Therapeutics has a consensus target price of $18.75, indicating a potential upside of 288.20%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Prestige Consumer Healthcare.

Institutional & Insider Ownership

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 1.5% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Prestige Consumer Healthcare beats Unicycive Therapeutics on 8 of the 13 factors compared between the two stocks.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.